Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BioChaperone Pramlintide + human insulin
- Development stage
- Unknown
- Lead developer
- Adocia
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Administration
- Subcutaneous
01
Overview
BioChaperone Pramlintide + human insulin is a fixed-ratio co-formulation developed by Adocia for the mealtime (prandial) treatment of type 1 and type 2 diabetes. It combines human insulin with pramlintide, an amylin analog, using Adocia's proprietary BioChaperone technology. This technology enables the stabilization and solubilization of both biologics at a neutral pH in a single injection, mimicking the physiological co-secretion of insulin and amylin from pancreatic beta cells. The combination aims to provide superior postprandial glycemic control and reduce the treatment burden by eliminating the need for separate injections of insulin and amylin analogs. Phase 1 clinical trials have demonstrated improved blood glucose control compared to separate injections or insulin lispro alone.
- Other names
- BioChaperone Pramlintide Insulin
02
Targets
AMY receptor (Calcitonin receptor (with ramps))INSR (Insulin receptor)
Beyond the preview
Go deeper on BioChaperone Pramlintide + human insulin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BioChaperone Pramlintide + human insulin.